Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

The biotech announced good news. But investors could be worried about external factors.

Why Novavax Stock Sank Today

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Novavax (NVAX) Q4 Earnings Expected to Decline

Shares of Novavax Inc. were down 6.2% in trading on Monday after the company said it had completed enrollment of the Phase 3 clinical trial for its COVID-19 vaccine candidate in Mexico and the U.S. Novavax said that 20% of the roughly 30,000 trial participants are LatinX, 13% are African Americans, 6% are Native Americans, and 5% are Asian Americans. Separately, 13% of all trial participants are 65 years old or older.

Novavax completes enrollment in Phase 3 clinical trial for its COVID-19 vaccine candidate

Novavax, Inc. (NASDAQ: NVAX) has taken another step toward obtaining emergency use authorization for NVX-CoV2373, its recombinant protein-based vaccine candidate against the novel coronavirus. What Happened: Maryland-based Novavax said it has completed enrollment of the PREVENT-19, pivotal Phase 3 study in the U.S. and Mexico, that is evaluating the efficacy, safety and immunogenicity of NVX-CoV2373.

Novavax Achieves Target Enrollment In Pivotal Phase 3 Coronavirus Vaccine Study In US, Mexico

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company's COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

Since January 2020, Novavax has become 65-bagger. Is it still a buy?

3 Green Flags for Novavax Investors, and 1 Red Flag

Moderna

There's plenty to like about both of these high-flying biotech stocks.

Better Coronavirus Stock: Moderna or Novavax?

Evolus

Vaccinex Inc

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechnology company that develops vaccines.

Why Novavax, Vaccinex, Evolus Are Trading Higher Today

Shares of Novavax jumped 10% on Friday after the biotech firm announced that it would supply over 1.1 billion doses of COVID-19 vaccines as part of a global initiative.  The Gaithersburg, Maryland-based company late Thursday unveiled a memorandum of understanding with GAVI, the Global Alliance for Vaccines and Immunization, to provide its vaccine to the COVID-19 Vaccines Global Access (COVAX) initiative in a global push to guarantee fair and equitable vaccine distribution.

Novavax jumps 10% on deal to provide over 1 billion doses of its COVID-19 vaccine globally

Novavax, Inc. (NASDAQ: NVAX) shares raced to an all-time $331.68 on Feb. 9 before beginning to lose steam. Shares have declined for seven consecutive sessions since then, but a positive release from the company is lifting the stock.

Novavax On Track To Snap Losing Streak On Massive Vaccine Supply Deal

This stock isn't a sure thing. But it's a lot closer to being one than Ocugen.

Forget Ocugen! Here's a COVID Stock That Could Make You Richer Quicker

GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavax' recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility. The vaccine doses will be manufactured and distributed globally by Novavax and Serum Institute of India (SII), the latter under an existing agreement between Gavi and SII. NVX-CoV2373 is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom (U.K.), for the prevention of COVID-19. Novavax has previously reported positive interim efficacy results from its U.K. trial.

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

AstraZeneca

BioNTech SE

Johnson & Johnson

Pfizer

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

Novavax stock has had a stellar run, more than doubling since early January 2021 driven by promising efficacy data for its Covid-19 vaccine. The stock is also up about 30x over the last 12 months.

Is Novavax Stock Too Risky At $260?

This investigational vaccine showed it could handle one of today's biggest risks.

Is Novavax Stock a Good Bet on Coronavirus Vaccines?

Though RNA vaccines may have jumped to the lead, the complexities of the Covid-19 crisis gives NVAX stock some extra room to run even higher. The post Despite Huge Run, There's Still Some Upside for Novavax appeared first on InvestorPlace.

Despite Huge Run, There's Still Some Upside for Novavax

Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government

Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

The stock's gains could continue despite a chink in its armor.

1 Green Flag and 1 Red Flag for Novavax's Vaccine Candidate

The biotech's vaccine could be the most effective of all against the most prevalent coronavirus strain.

Why Novavax's COVID Vaccine Results Were So Stellar

Here's Why the Novavax Vaccine May Have to Wait for FDA Authorization

All American adults could potentially be fully vaccinated this year with only Pfizer's and Moderna's vaccines.

Could the U.S. Buying More COVID Vaccines Hurt Johnson & Johnson and Novavax?

It may be behind, but the biotech's clinical trial data looked good.

Novavax Gets the Job Done With its COVID Vaccine

Could Novavax Win U.S. Authorization for Its COVID Vaccine Sooner Than Expected?

The chances look pretty good that the biotech stock will continue its winning ways.

News for Novavax Stock (NVAX)